SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA
Nephrol Dial Transplant. 2020 Oct 1;35(10):1825.
doi: 10.1093/ndt/gfz137.